Office-Based Injection Treatment Targeting Superior Laryngeal Nerve for Chronic Neurogenic Cough

What this Trial Is About

Researchers are evaluating an office-based injection called a superior laryngeal nerve SLN block to see if it can reduce cough frequency and ease symptoms in people with neurogenic cough, a chronic cough thought to be caused by irritation of a nerve related to the voice box. This cough type often follows an upper respiratory infection and current treatments include oral medications that can cause sedation and other side effects. The study aims to expand on earlier findings by using more methods to assess the severity of cough symptoms in a larger group of patients. Participants will receive a unilateral injection of a mixture of a local anesthetic bupivacaine and steroid Kenalog-40 near the superior laryngeal nerve on the side showing the most discomfort or cough sensitivity. If no side is specifically affected, the injection will be done on the right side. This procedure is done in an office setting and is being studied as an alternative to oral medications for chronic cough management. During the study, participants cough symptoms will be measured using the Leicester Cough Questionnaire at the start and again after three months to assess changes. Patients will be monitored for symptom changes and any side effects from the injection. The total participation duration includes at least three months of follow-up to evaluate the treatment impact and safety. The study is sponsored by the University of Alabama at Birmingham and aims to better understand this nerve blocks role in treating neurogenic cough.

Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough